mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer

Endocrine-Related Cancer

Volumn 19, Issue 1, 2012, Pages 1-12

  Schiewer, Matthew J ^a,b   Den, Robert ^b   Hoang, David T ^a,b   Augello, Michael A ^a,b   Lawrence, Yaacov R ^b   Dicker, Adam P ^b   Knudsen, Karen E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; RADIOSENSITIZING AGENT; TARGET OF RAPAMYCIN KINASE;

ADJUVANT THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ASSESSMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PHENOTYPE; RADIOSENSITIZATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE; X RAY;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RECEPTORS, ANDROGEN; SIROLIMUS; TOR SERINE-THREONINE KINASES; X-RAYS;

EID: 84860343387     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0072     Document Type: Article

References (54)

1. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E & Faivre S 2008 Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemotherapy and Pharmacology 62 305-313. (doi:10.1007/s00280-007- 0609-2)
2. Allen GW, Howard AR, Jarrard DF & Ritter MA 2007 Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 110 1405-1416. (doi:10.1002/cncr.22940)
3. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R et al. 2010 A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research 16 3057-3066. (doi:10.1158/1078-0432.CCR-10-0124)
4. Baldin V, Lukas J, Marcote MJ, Pagano M & Draetta G 1993 Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes and Development 7 812-821. (doi:10.1101/gad.7.5.812)
5. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA & Thomas G 2005 The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 747-759. (doi:10.1016/j.cell.2004.12.040)
6. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ & Lucia MS 2003 Molecular characterization of human prostate carcinoma cell lines. Prostate 57 205-225. (doi:10.1002/pros. 10290)
7. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C et al. 2002 Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 103-106. (doi:10.1016/S0140-6736(02)09408-4)
8. Braunstein S, Badura ML, Xi Q, Formenti SC & Schneider RJ 2009 Regulation of protein synthesis by ionizing radiation. Molecular and Cellular Biology 29 5645-5656. (doi:10.1128/MCB.00711-09)
9. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS & Sidransky D 1997 Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Research 57 4997-5000. (Pubitemid 27498107)
10. Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ & Lu B 2006 Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagyand radiosensitizes PTEN null prostate cancer cells. Cancer Research 66 10040-10047. (doi:10.1158/0008-5472.CAN-06-0802)
11. Chen Y, Sawyers CL & Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology 8 440-448. (doi:10.1016/j.coph.2008.07.005)
12. Chen H, Ma Z, Vanderwaal RP, Feng Z, Gonzalez-Suarez I, Wang S, Zhang J, Roti Roti JL & Gonzalo S 2010 The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiation Research 175 214-224.
13. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JK, Ampil F, Glass J & Nathan CO 2009 Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Molecular Cancer Therapeutics 8 2255-2265. (doi:10.1158/1535-7163.MCT-08-1184)
14. Fung AS, Wu L & Tannock IF 2009 Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clinical Cancer Research 15 5389-5395. (doi:10.1158/1078-0432.CCR-08-3007)
15. Gao N, Zhang Z, Jiang BH & Shi X 2003 Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochemical and Biophysical Research Communications 310 1124-1132. (doi:10.1016/j.bbrc.2003.09. 132)
16. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB & Hidalgo M 2002 Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Research 62 6141-6145. (Pubitemid 35244463)
17. Hidalgo M & Rowinsky EK 2000 The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 6680-6686. (doi:10.1038/sj.onc.1204091)
18. Hirabayashi N, Noso Y, Niimi K, Nishiyama M, Yamaguchi M, Toge T, Niimoto M & Hattori T 1987 Comparative studies on in vitro human tumor clonogenic assay (HTCA) and in vivo nude mouse-isotope assay (NM-IA). Japanese Journal of Surgery 17 104-109. (doi:10.1007/BF02470649)
19. Huang JJ, Li ZM, Huang Y, Tian Y, He XX, Xiao J & Lin TY 2010 Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs. Investigational New Drugs [in press]. (doi:10.1007/s10637-010-9558-4)
20. Jemal A, Siegel R, Xu J & Ward E 2010 Cancer statistics. CA: A Cancer Journal for Clinicians 60 277-300. (doi:10.3322/caac.20073)
21. Klein EA, Ciezki J, Kupelian PA & Mahadevan A 2009 Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urologic Oncology 27 67-71. (doi:10.1016/j.urolonc. 2008.04.001)
22. Klotz L 2006 Combined androgen blockade: an update. Urologic Clinics of North America 33 161-166. (doi:10.1016/j.ucl.2005.12.001)
23. Knudsen KE & Scher HI 2009 Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clinical Cancer Research 15 4792-4798. (doi:10.1158/1078-0432.CCR-08-2660)
24. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA & Nagle RB 2006 Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66 1203-1212. (doi:10.1002/pros.20410)
25. Kwok Y & Yovino S 2010 Update on radiation-based therapies for prostate cancer. Current Opinion in Oncology 22 257-262. (doi:10.1097/CCO. 0b013e3283378c84)
26. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J et al. 2007 Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology 25 1596-1605. (doi:10.1200/JCO.2006.10. 1949)
27. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M & Hirakawa K 2009 Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Science 100 2402-2410. (doi:10.1111/j.1349-7006.2009.01315.x)
28. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M &Sellers WR 1999 Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Research 59 4291-4296. (Pubitemid 29418745)
29. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL & Corey E 2008 RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68 861-871. (doi:10.1002/pros.20752)
30. Morgan TM, Koreckij TD & Corey E 2009 Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Current Cancer Drug Targets 9 237-249. (doi:10.2174/156800909787580999)
31. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 449-456. (doi:10.1016/S0140-6736(08)61039-9)
32. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB &Kallioniemi OP 2001 Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20 6718-6723. (doi:10.1038/sj.onc.1204889)
33. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME & Hamstra DA 2009 Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clinical Cancer Research 15 589-596. (doi:10.1158/1078-0432.CCR-08- 1019)
34. Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T & Taniguchi S 2010 Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. International Journal of Oncology 37 1001-1010. (doi:10.3892/ijo-00000751)
35. van der Poel HG, Hanrahan C, Zhong H & Simons JW 2003 Rapamycin induces Smad activity in prostate cancer cell lines. Urological Research 30 380-386. (doi:10.1007/s00240-002-0282-1)
36. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A & Saadati HR 2007 Role of PTEN gene in progression of prostate cancer. Urology Journal 4 95-100.
37. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS & Beer TM 2010 CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70 433-442. (doi:10.1002/pros.21077)
38. Sansal I & Sellers WR 2004 The biology and clinical relevance of the PTEN tumor suppressor pathway. Journal of Clinical Oncology 22 2954-2963. (doi:10.1200/JCO.2004.02.141)
39. Saunders PO, Cisterne A, Weiss J, Bradstock KF & Bendall LJ 2011 The mTOR inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B ALL. Haematologica 96 69-77.
40. Schayowitz A, Sabnis G, Goloubeva O, Njar VC & Brodie AM 2010 Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. British Journal of Cancer 103 1001-1007. (doi:10.1038/sj.bjc.6605882)
41. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK et al. 2010 The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation 120 4478-4492. (doi:10.1172/JCI44239)
42. Shen C, Lancaster CS, Shi B, Guo H, Thimmaiah P & Bjornsti MA 2007 TOR signaling is a determinant of cell survival in response to DNA damage. Molecular and Cellular Biology 27 7007-7017. (doi:10.1128/MCB.00290-07)
43. Sinclair WK & Morton RA 1966 X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiation Research 29 450-474. (doi:10.2307/3572025)
44. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG et al. 2009 PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. Journal of Pathology 218 505-513. (doi:10.1002/path.2559)
45. Taplin ME 2007 Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nature Clinical Practice. Oncology 4 236-244. (doi:10.1038/ncponc0765)
46. Tirado OM, Mateo-Lozano S, Sanders S, Dettin LE &Notario V 2003 The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of rapamycin in the response of normal fibroblasts to ionizing radiation. Cancer Research 63 6290-6298. (Pubitemid 37255176)
47. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB & Sawyers CL 1998 Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. PNAS 95 5246-5250. (doi:10.1073/pnas.95.9.5246)
48. Wilson AP, Ford CH, Newman CE & Howell A 1984 A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. British Journal of Cancer 49 57-63. (doi:10.1038/bjc.1984.9)
49. Wu L, Birle DC & Tannock IF 2005 Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Research 65 2825-2831. (doi:10.1158/0008- 5472.CAN-04-3137)
50. Xu W, Ngo L, Perez G, Dokmanovic M & Marks PA 2006a Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. PNAS 103 15540-15545. (doi:10.1073/pnas. 0607518103)
51. Xu Y, Chen SY, Ross KN & Balk SP 2006b Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Research 66 7783-7792. (doi:10.1158/0008-5472.CAN-05-4472)
52. Yau TM, Kim SC, Nygaard OF, Gregg EC & Crissman HA 1980 Correlation of cell cycle parameters with radiation sensitivity in a series of murine L5178Y cells. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine 37 429-435. (doi:10.1080/09553008014550501)
53. Yuan X & Balk SP 2009 Mechanisms mediating androgen receptor reactivation after castration. Urologic Oncology 27 36-41. (doi:10.1016/j. urolonc.2008.03.021)
54. Yung WK 1989 In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurgical Review 12 197-203. (doi:10.1007/BF01743984)